36th European Association for the Study of Diabetes (EASD) Annual Meeting, 17-21 September, 2000

On behalf of SmithKline Beecham we are delighted to be able to offer you exclusive interviews with leading experts on Avandia.

Monday 18 September, 2000
Tuesday 19 September, 2000

• With the European approval of Avandia, SmithKline Beecham's new oral anti-diabetic agent, a new treatment option is available to patients with inadequately controlled type 2 diabetes.

• Avandia is the first thiazolidinedione to receive centralized approval across the 15 countries of the European Union and has been approved in over 50 countries worldwide.

• Avandia has been linked with improvements in �-cell function and reductions in insulin resistance, both fundamental causes of type 2 diabetes.

• To date, over 4 million Avandia prescriptions have been dispensed to over a million patients in the US alone.

We are delighted to be able to offer you the opportunity to interview some of the world's leading experts in diabetes in exclusive one-on-one interviews.

If you are attending EASD, a range of experts will be available for face-to-face interviews on the afternoon of Monday 18 September and morning of Tuesday 19 September, 2000, local time. Interviews can also be conducted via telephone if you do not plan to attend the conference.

To reserve your interview time, please complete the attached fax-back form and return to Chloe Murray on +44 [0]20 7398 0501.

FAX-BACK FORM

EASD, 2000, Jerusalem, Israel

Interviews with leading experts

Name:
Publication:
Telephone number:
Fax number:
Email address:

I am attending EASD 2000, Jerusalem and would like to conduct face-to-face interviews: ___

I am not attending EASD 2000, Jerusalem and would like to conduct telephone interviews: ___

My preferred day for interviews is:

Monday 18 September, pm ___
Tuesday 19 September, am ___

We will contact you confirming your interview and providing details of timings and venue.

Please note: Israel local time = GMT +02:00

Please fax this form back to: Chloe Murray at MediTech Media on +44 [0]20 7398 0501